Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study

Sebastian Stintzing,Ilse van Oostrum,Chris P. Pescott,Philippe Ronga,Bart Heeg,Volker Heinemann

Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study

2020

Sebastian Stintzing
Ilse van Oostrum
Chris P. Pescott
Philippe Ronga
Bart Heeg
Volker Heinemann

AbstractAims: This analysis evaluates the cost-effectiveness of first-line treatment with FOLFIRI + cetuximab vs FOLFIRI + bevacizumab (FOLFIRI-cet vs FOLFIRI-bev) for patients with RAS wild-type (...

Keywords:

Wild type
Intensive care medicine
Bevacizumab
Internal medicine
Oncology
Colorectal cancer
Medicine
first line
Cetuximab
FOLFIRI
first line treatment
cost effectiveness

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations